European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"[99mTc]Tc-sestamibi SPECT/CT for the diagnosis of kidney tumours: a multi-centre feasibility study (MULTI-MIBI Study).","authors":"Hannah Warren,Thomas Wagner,Soha El-Sheikh,Nick Campain,Tze M Wah,Tim S O'Brien,Iosif A Mendichovszky,Sabina Dizdarevic,Charlie Stewart,Helen Ng,James Blackmur,Patrick Rogers,Andrew Scarsbrook,Dhruba Dasgupta,Fahim Ul-Hassan,Nitasha Singh,Ammar Alanbuki,Maryam Jessop,Linda Park,Kelly Leonard,Alex Wood,Ben Challacombe,Grant D Stewart,Ravi Barod,Prasad Patki,Faiz Mumtaz,Axel Bex,Veeru Kasivisvanathan,William Wildgoose,Sigrun Clark,Cecilia Vindrola-Padros,Elena Pizzo,Hakim-Moulay Dehbi,Mark Emberton,Maxine Gb Tran","doi":"10.1007/s00259-025-07525-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07525-3","url":null,"abstract":"PURPOSE[99mTc]Tc-sestamibi SPECT/CT (MIBI SPECT/CT) is a promising tool to differentiate benign and malignant renal tumours. We tested feasibility of recruitment to a prospective, multi-centre diagnostic test evaluation study of MIBI SPECT/CT for T1 renal tumours.METHODSConsecutive adult patients with a newly-diagnosed clinical T1 (cT1) renal mass (2-7 cm) presenting to participating sites December 2022 - February 2024 were recruited and underwent MIBI SPECT/CT prior to histopathological diagnosis. Patients who accepted and declined participation and clinicians involved in study activities were invited to a semi-structured interview. The primary endpoint was feasibility of multi-centre recruitment. Secondary endpoints included qualitative assessment of barriers and facilitators to participation, estimates of MIBI SPECT/CT accuracy to detect cancer in order to power a definitive study, inter-rater agreement and identifying training needs for scan acquisition and interpretation.RESULTSOf 109 approached patients, 50 enrolled and underwent the study scan (45.8%, 95% CI 36.2-55.7%) across 6 sites. MIBI SPECT/CT scans were acquired and reported without the need for significant additional training. All scans were of adequate quality for interpretation. Sensitivity and specificity of MIBI SPECT/CT to detect cancer were 97.0% (95% CI 84.2-99.9%) and 53.8% (25.1-80.8%), respectively.CONCLUSIONMULTI-MIBI has demonstrated feasibility of recruitment to a diagnostic evaluation study for T1 renal masses. Preliminary estimates of diagnostic accuracy suggest that MIBI SPECT/CT could reduce the number of patients with benign tumours undergoing surgery without missing a significant number of patients with malignant disease, however these results are limited by the small sample size in this feasibility study and a larger definitive study is needed prior to adoption in practice.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"89 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data.","authors":"Caroline Boursier,Timothée Zaragori,Nicolas Garabedian,Marie Blonski,Tiphaine Obara,Luc Taillandier,Laetitia Imbert,Antoine Verger","doi":"10.1007/s00259-025-07555-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07555-x","url":null,"abstract":"PURPOSEThis study aimed to reveal the factors affecting the therapeutic response of refractory meningiomas treated with [177Lu]Lu-DOTATATE and to collect initial tumor absorbed doses.METHODSPatients with refractory and progressive meningiomas treated with [177Lu]Lu-DOTATATE from 2021 to 2024 were retrospectively included. Association analyses of clinical factors, WHO grade, prior therapy (surgery, radiation, systemic therapy: bevacizumab or a combination of octreotide/everolimus), 3D-MRI volume and pretreatment PET parameters with 6-month progression-free survival (PFS-6), as defined by the 3D-RANO criteria, were performed. Growth rates obtained via MRI and tumor absorbed doses (TAD) were also calculated.RESULTSSixteen patients (60 [55;68] years old) underwent 4 [2;4] cycles of [177Lu]Lu-DOTATATE, with a TAD/cycle of 0.45 [0.30;0.83] Gy/GBq/cycle. Only prior systemic therapy was found as a risk factor for PFS-6 (p ≤ 0.05), with an impact on tumor growth rate (TGR) (4 vs. 12 patients, + 125% vs. -107%, p < 0.01). For the 12 patients without any prior systemic therapy, the PFS-6 was 67% (8/12 patients) whereas it was 0% in the other group, those with prior systemic therapy. No associations between the TAD and difference in the TGR before/after SSTR-RT were observed in the overall population (p = 0.10) or in the population of patients without any prior therapy (p = 0.72).CONCLUSION[177Lu]Lu-DOTATATE appears effective in refractory meningiomas with no prior systemic therapy, even if the TADs are relatively low. [177Lu]Lu-DOTATATE should be proposed as early as possible in the treatment course of refractory meningiomas.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"1 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145103380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT.","authors":"Huanyu Gong,Yong Cheng,Qiang Li,Yingjun He,Qijun Cai,Yongjin Tang,Yulong Liu,Lu Kuang,Yingxin Li,Jingjie Shang,Chengzhi Li,Kangshou Liu,Mingrong Cao,Lu Wang,Xueying Ling,Hao Xu","doi":"10.1007/s00259-025-07548-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07548-w","url":null,"abstract":"PURPOSESThis study aimed to evaluate the diagnostic value of 18F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma(uHCC) and with a comparative analysis against 18F-FDG PET/CT.METHODSPatients with uHCC who underwent paired 18F-FDG and 18F-FAPI-04 PET/CT for pre-treatment staging or post-treatment restaging were retrospectively included. The two tracers were compared in terms of their ability to detect intrahepatic and extrahepatic lesions, including sensitivity, maximum standardized uptake value (SUVmax), and tumour-to-background ratio (TBR).RESULTSEighty-five patients (mean age: 53.9 ± 10.0 years) were included. In patient-based analysis, 18F-FAPI-04 showed higher intrahepatic lesion detection sensitivity (98.8% vs. 85.9%, P = 0.003) and lesion uptake than 18F-FDG (median maximum SUVmax:9.1 vs. 7.6, P = 0.028). Contrast enhanced CT/MRI(CECT/MR) demonstrated comparable sensitivity to 18F-FAPI-04 PET and superior to 18F-FDG PET (96.5% vs. 85.9%, P = 0.004). In lesion-based analysis, 18F-FAPI-04 demonstrated significantly higher sensitivity (89.5% vs. 57.1%, P < 0.001), intrahepatic lesion SUVmax, (median:6.5 vs. 3.7, P < 0.001) and TBR (median:3.4 vs. 1.7, P < 0.001) than 18F-FDG, but lower sensitivity than CECT/MR (89.5% vs. 96.2%, P < 0.001). Among organ transplant recipients, 18F-FDG showed superior sensitivity to 18F-FAPI-04 for detecting intrahepatic lesions (87.5% vs. 37.5%, P = 0.002). 18F-FDG had a higher detection rate of portal vein tumour thrombosis (PVTT) (95.7% vs. 43.5%, P = 0.002), lymph node metastasis (95.7% vs. 82.8%, P = 0.004), and lung metastasis (69.3% vs. 58.4%, P = 0.007).18F-FAPI-04 was significantly better than 18F-FDG in detecting peritoneal metastasis (100% vs. 69.6%, P = 0.016). According to 18F-FAPI-04 PET/CT, Barcelona Clinic Liver Cancer (BCLC) and China Liver Cancer (CNLC) staging were changed in 16 (18.8%) and 22 (25.9%) patients, respectively.CONCLUSIONS18F-FAPI-04 exhibits significant diagnostic advantages in uHCC patients, particularly in the detection of intrahepatic lesions, peritoneal metastases, and better contrast compared with 18F-FDG. Among organ transplant recipients,18F-FDG may offer higher sensitivity than 18F-FAPI-04 for intrahepatic lesion detection. 18F-FDG outperforms 18F-FAPI-04 in identifying PVTT. The rational selection of these two tracers may improve the accuracy of clinical staging.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"112 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145103346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline [18F]FDG PET/CT characterization of extramedullary disease and prognostic value in relapsed/refractory B-cell acute lymphoblastic leukemia treated with CAR-T cells.","authors":"Xilan Yao,Lijing Wei,Hongrong Wang,Xiao Lei,Zheqin Wang,Shuang Yao,Jigang Yang","doi":"10.1007/s00259-025-07562-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07562-y","url":null,"abstract":"PURPOSEThis study aimed to characterize the non-central nervous system extramedullary disease (non-CNS EMD) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and to evaluate the prognostic value of metabolic parameters derived from [18F]FDG PET/CT imaging.METHODSPatients with r/r B-ALL who received chimeric antigen receptor (CAR)-T cell therapy and underwent [18F]FDG PET/CT before CAR-T cell therapy were retrospectively enrolled. Lesions were semi-automatically segmented using LIFEx software, based on a threshold of 41% of the maximal uptake value. The anatomical locations of FDG-avid lesions were summarized to delineate the characteristics of non-CNS EMD. Furthermore, metabolic parameters from FDG PET/CT (SUVmax, MTV, and TLG) as well as selected clinical and laboratory features were collected. These variables were categorized into two groups for survival analysis. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.RESULTSA total of 81 B-ALL patients were included in this study. The most frequently observed non-CNS EMD lesions involved the lymph node, spleen, and kidney. After a median follow-up time of 23.7 months, multivariate analysis identified hemoglobin (Hb) and SUVmax (with a cut-off value of 7.0) as independent prognostic factors for PFS and OS. Patients with abnormal Hb levels exhibited significantly shorter PFS and OS compared to those with normal Hb levels (median PFS: 13.5 months vs. not reached, P = 0.004; median OS: 48.0 months vs. not reached, P = 0.010). Similarly, patients with SUVmax above the threshold had significantly reduced PFS and OS compared to those below the threshold (median PFS: 9.1 months vs. not reached, P ≤ 0.001; median OS: 27.0 months vs. 50.8 months, P = 0.020).CONCLUSION[18F]FDG PET/CT effectively visualizes extramedullary infiltration in patients with B-ALL, and these non-CNS EMD lesions were also associated with clinical outcomes. SUVmax serves as a valuable predictive biomarker for both PFS and OS.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"14 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical evaluation of dynamic [18F]FDG PET imaging to distinguish infection from inflammation in fracture-related infections.","authors":"N D van Rijsewijk,M Wouthuyzen-Bakker,J H van Snick,J van Sluis,R H J A Slart,A W J M Glaudemans,F F A IJpma","doi":"10.1007/s00259-025-07563-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07563-x","url":null,"abstract":"BACKGROUNDStandard [18F]FDG PET/CT is widely used to detect infections, but is limited in differentiating bacterial infection from inflammation due to overlapping uptake patterns. This distinction is particularly challenging in fracture-related infection (FRI), due to multiple factors, including recent surgery, soft tissue injury, fracture healing, and surgical implants. Dynamic [18F]FDG imaging over time may overcome this limitation by capturing a rapid, sustained uptake seen in infections, driven by ongoing immune and microbial activity, as opposed to the potentially slower uptake in inflammation. This study investigates the potential of dynamic [18F]FDG PET/CT using time-activity curves (TACs) to distinguish infection from inflammation in patients with suspected FRI.METHODSA prospective study was performed in patients referred for [18F]FDG PET/CT examination to detect (the extent of) FRI from December 2021 until November 2024. Final clinical diagnosis of FRI was established according to the criteria defined by the FRI consensus group and used as a reference standard. Dynamic PET imaging was performed using a long axial field-of-view PET/CT system over a 65-minute period after [18F]FDG injection. TACs were analyzed to compare uptake patterns between confirmed infections and inflammation, and diagnostic accuracy was calculated and compared to conventional standard imaging.RESULTSThirty-one patients with 33 fractures suspected of infection were included. Infection was clinically confirmed in 14 fractures (42%). Diagnosis of FRI based on dynamic imaging using TACs resulted in a high sensitivity of 86%, specificity of 100%, PPV of 100% and NPV of 90%, resulting in a diagnostic accuracy of 94%. In the infection group, Fracture SUVpeak increased progressively over time, while in the inflammation group, uptake appeared to reach a plateau (p < 0.001). Visual interpretation of the dynamic imaging yielded a diagnostic accuracy of 82%. For standard imaging, quantitative and visual assessments showed diagnostic accuracies of 91% and 88%, respectively.CONCLUSIONThis proof-of-concept study demonstrates that dynamic [18F]FDG PET/CT using TACs can distinguish infection from inflammation in patients with suspected FRI, with high diagnostic accuracy observed, and suggesting a potential advantage over standard imaging. Larger-scale studies are needed to validate these results and explore the full clinical potential of dynamic imaging in infection management.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"90 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting of fibroblast activation protein with [161Tb]Tb-FAP-2286 in treatment-refractory non-small cell lung cancer.","authors":"Swagat Dash,Vindhya Malasani,Rakhee Vatsa,Majid Assadi,Habibollah Dadgar,Hossein Arabi,Ashok Kumar,Dinesh Pendharkar","doi":"10.1007/s00259-025-07553-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07553-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"16 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging policy and innovation: SPARC-Europe's vision for radioligand therapy in cancer care.","authors":"Nicola Fazio,Ignasi Carrio Gasset,Ken Hermann","doi":"10.1007/s00259-025-07534-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07534-2","url":null,"abstract":"SPARC-Europe, the Stakeholder Political Alliance for Radioligand Cancer Therapies, was launched in October 2020. It represents an ambitious and collaborative initiative aimed at improving outcomes for cancer patients across Europe by advancing the policy and infrastructure needed to institutionalize Radioligand Therapies (RLTs). The current steering committee comprises several types of health care professionals, such as nuclear medicine specialists, clinicians, nurses, physicists, radio-pharmacists, and patient advocates, under a shared vision. Since its inception, SPARC-Europe has achieved several notable milestones, including the publication of a high-level position paper on improving access to RLTs., the production of an investment pathway document to guide infrastructure development, the recording of compelling patient testimony videos to humanize the need for expanded access, the organization of two influential policy events dedicated to RLTs, the support of motions for resolutions in the European Parliament that call for investments in radionuclide supply and hospital infrastructure. SPARC-Europe is continuing to deepen its work through targeted research and pilot programs, including the RADAR (Radioligand Awareness Research), a global survey focused on neuroendocrine neoplasms and prostate cancer to assess awareness, accessibility, and perceptions of RLTs among patients and physicians. By bringing together policy, science, and patient advocacy, SPARC-Europe is not only supporting innovation but actively shaping the frameworks needed to deliver it to those who need it most. As the European health landscape continues to evolve, SPARC-Europe offers a model for how patient-centered, evidence-based, and policy-savvy coalitions can drive meaningful change.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"77 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145089763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paraganglia.","authors":"Sophie C Siegmund,Adrien Holzgreve,Magdalena Schöll,Vera U Wenter,Gabriel T Sheikh,Maximilian Scheifele,Franz Josef Gildehaus,Simon Lindner,Matthias K Auer,Christian Lottspeich,Matthias Kroiß,Svenja Nölting,Friederike Völter,Christine Spitzweg,Christoph J Auernhammer,Rudolf A Werner,Mathias J Zacherl","doi":"10.1007/s00259-025-07550-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07550-2","url":null,"abstract":"PURPOSEIn somatostatin receptor (SSTR)-expressing tumors, theranostics with SSTR-directed imaging and therapy showed promising results regarding disease control. This study evaluated the use of PET imaging with [18F]SiTATE in pheochromocytoma and paraganglioma (PPGL) patients, focusing on eligibility for peptide radioreceptor therapy (PRRT) and therapy monitoring.METHODSFive patients with metastatic paraganglioma (n = 3) or pheochromocytoma (n = 2) were included. Eligibility for PRRT was assessed by [18F]SiTATE applying the Krenning score and baseline SUVmax. Treatment response was analyzed by RECIST 1.1 criteria, total tumor volume (PET-based TTV), and Chromogranin A (CgA).RESULTSAt baseline, all patients showed high lesional uptake, with the highest in the bone (mean SUVmax 41.4 ± 87.3) and a high Krenning Score of 3-4, Suggestive for PRRT eligibility. At the follow up, 2.5 months after completion of PRRT, all patients presented with stable disease (RECIST 1.1) and decreasing or stable CgA levels, whereas TTV increased in three patients and thus showed heterogenous response.CONCLUSIONIn metastatic PPGL, [18F]SiTATE effectively visualizes tumor burden and supports patient selection and response assessment for PRRT. Notably, the data revealed a heterogenous response across PET-based, CT-based, and biochemical assessments. The underlying mechanisms of these discrepancies remain unclear and warrant further investigation.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"16 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145083486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG PET/CT for outcome prediction in diffuse large B-cell lymphoma treated with polatuzumab vedotin-containing regimens.","authors":"Congcong Yu,Jing Wang,Lin Chen,Rui Zhou,Xiaofeng Dou,Mei Tian,Hong Zhang,Xiaohui Zhang,Chentao Jin","doi":"10.1007/s00259-025-07561-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07561-z","url":null,"abstract":"PURPOSETo investigate the prognostic values of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) treated with Polatuzumab vedotin (Pola)-containing regimens.MATERIALS AND METHODSThirty-nine patients who received Pola-containing regimens and underwent pre-treatment [18F]FDG PET/CT were retrospectively enrolled and followed up. Qualitative response was assessed using Lugano criteria on follow up PET. Quantitative [18F]FDG PET parameters including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were evaluated using two segmentation methods (SUV 4.0 and 41% SUVmax), and changes in these indices (Δvalues) between pre-Pola and first follow-up PET scans were calculated. The prognostic values of PET metabolic parameters, clinical characteristics, and laboratory indicators were evaluated using time-dependent receiver operating characteristic (ROC) curve, and Cox regression analysis. Survival functions were estimated by Kaplan-Meier analysis.RESULTSThe median follow-up duration was 17.2 months (range 3.28 months - 26.2 months). During this period, 16 patients (41.0%) experienced progression. Patients with complete metabolic responses (CMR) exhibited superior outcomes than patients with partial metabolic responses (PMR). ROC and Cox analysis demonstrated that MTV and TLG based on SUV 4.0 segmentation showed superior predictive performance than those based on the 41% SUVmax method. Multivariate Cox regression analysis identified SUVmean (P = 0.016, HR = 1.27) and MTV (P = 0.002, HR = 1.01) on first follow-up PET as independent predictors of progression-free survival (PFS).CONCLUSIONCMR patients exhibited superior outcomes than PMR patients, and SUVmean and MTV on the first follow-up PET were independent predictors of PFS, suggesting that [18F]FDG PET/CT may play an important role in predicting outcomes of DLBCL patients treated with Pola-containing regimens.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"16 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145083423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparisons of PET tracers in oncology: pitfalls and challenges. The lesson from neuroblastoma.","authors":"Francesco Fiz,Arnoldo Piccardo,Giorgio Treglia","doi":"10.1007/s00259-025-07551-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07551-1","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"10 6 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145077727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}